- AstraZeneca's oncology head says the company is targeting deals for drugs with potential for combinations.
AstraZeneca's oncology head says the company is seeking deals for drugs with potential for combinations, underscoring a strategic focus on combination therapies. No specific targets or terms were disclosed.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.